{"id":48099,"date":"2022-09-08T12:02:44","date_gmt":"2022-09-08T10:02:44","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/global-waldenstrom-macroglobulinemia-wm-marketed-and-pipeline-drugs-assessment-clinical-trials-and-competitive-landscape-report-2022-researchandmarkets-com\/"},"modified":"2022-09-08T12:02:44","modified_gmt":"2022-09-08T10:02:44","slug":"global-waldenstrom-macroglobulinemia-wm-marketed-and-pipeline-drugs-assessment-clinical-trials-and-competitive-landscape-report-2022-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/global-waldenstrom-macroglobulinemia-wm-marketed-and-pipeline-drugs-assessment-clinical-trials-and-competitive-landscape-report-2022-researchandmarkets-com\/","title":{"rendered":"Global Waldenstrom Macroglobulinemia (WM) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape Report 2022 &#8211; ResearchAndMarkets.com"},"content":{"rendered":"<div>\n<p>DUBLIN&#8211;(BUSINESS WIRE)&#8211;The <a target=\"_blank\" href=\"https:\/\/www.researchandmarkets.com\/reports\/5645167\/waldenstrom-macroglobulinemia-wm-marketed-and?utm_source=BW&amp;utm_medium=PressRelease&amp;utm_code=gw5vj5&amp;utm_campaign=1747120+-+Global+Waldenstrom+Macroglobulinemia+(WM)+Marketed+and+Pipeline+Drugs+Assessment%2C+Clinical+Trials+and+Competitive+Landscape+Report+2022&amp;utm_exec=jamu273prd\" rel=\"nofollow noopener\" shape=\"rect\">&#8220;Waldenstrom Macroglobulinemia (WM) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape&#8221;<\/a> report has been added to <strong>ResearchAndMarkets.com&#8217;s<\/strong> offering.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20220908005581\/en\/1565529\/4\/logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20220908005581\/en\/1565529\/21\/logo.jpg\"><\/a><\/p>\n<p>\nThis reports provides a data-driven overview of the current and future competitive landscape in Waldenstrom Macroglobulinemia therapeutics.\n<\/p>\n<p>\n<strong>Synopsis<\/strong>\n<\/p>\n<ul>\n<li>\nIn 2022, there will be more than 14,000 incident cases of WM across 16 pharmaceutical markets.\n<\/li>\n<li>\nThere are three leading marketed drugs for the treatment of WM, and Beigene is a key player in the disease space.\n<\/li>\n<li>\nA total of six pipeline drugs for WM are in late-stage (Phase III and Pre-registration) development.\n<\/li>\n<li>\nCommercial sponsors dominate clinical trial development in WM, with the US emerging as the key countries for conducting trials in WM.\n<\/li>\n<li>\nDeals involving partnerships were the most common type of deals globally, except in South America.\n<\/li>\n<li>\nTherapeutic options for WM patients continue to be limited, and no new therapy is expected to reach the US market in the next 12 months.\n<\/li>\n<\/ul>\n<p>\n<strong>Scope<\/strong>\n<\/p>\n<p>\nThe publisher&#8217;s combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.\n<\/p>\n<p>\n<strong>Components of the report include:<\/strong>\n<\/p>\n<ul>\n<li>\nDisease Landscape\n<\/li>\n<li>\nDisease Overview\n<\/li>\n<li>\nEpidemiology Overview\n<\/li>\n<li>\nTreatment Overview\n<\/li>\n<li>\nMarketed Products Assessment\n<\/li>\n<li>\nBreakdown by Mechanism of Action, Molecule Type and Route of Administration\n<\/li>\n<li>\nProduct Profiles with Sales Forecast\n<\/li>\n<li>\nPipeline Assessment\n<\/li>\n<li>\nBreakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration\n<\/li>\n<li>\nLate-to-mid-stage Pipeline Drugs\n<\/li>\n<li>\nPhase Transition Success Rate and Likelihood of Approval\n<\/li>\n<li>\nClinical Trials Assessment\n<\/li>\n<li>\nBreakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status\n<\/li>\n<li>\nEnrolment Analytics, Site Analytics, Feasibility Analysis\n<\/li>\n<li>\nDeals Landscape\n<\/li>\n<li>\nMergers, Acquisitions, and Strategic Alliances by Region\n<\/li>\n<li>\nOverview of Recent Deals\n<\/li>\n<li>\nCommercial Assessment\n<\/li>\n<li>\nKey Market Players\n<\/li>\n<li>\nFuture Market Catalysts\n<\/li>\n<\/ul>\n<p>\n<strong>Reasons to Buy<\/strong>\n<\/p>\n<ul>\n<li>\nDevelop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.\n<\/li>\n<li>\nDevelop business strategies by understanding the trends shaping and driving the Waldenstrom Macroglobulinemia market.\n<\/li>\n<li>\nDrive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Waldenstrom Macroglobulinemia market in the future.\n<\/li>\n<li>\nFormulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.\n<\/li>\n<li>\nIdentify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.\n<\/li>\n<li>\nOrganize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.\n<\/li>\n<\/ul>\n<p>\n<strong>Key Topics Covered:<\/strong>\n<\/p>\n<p>\n<strong>1 Preface<\/strong>\n<\/p>\n<p>\n<strong>2 Key Findings<\/strong>\n<\/p>\n<p>\n<strong>3 Disease Landscape<\/strong>\n<\/p>\n<p>\n3.1 Disease Overview\n<\/p>\n<p>\n3.2 Epidemiology Overview\n<\/p>\n<p>\n3.3 Treatment Overview\n<\/p>\n<p>\n<strong>4 Marketed Drugs Assessment<\/strong>\n<\/p>\n<p>\n4.1 Leading Marketed Drugs\n<\/p>\n<p>\n4.2 Overview by Mechanism of Action\n<\/p>\n<p>\n4.3 Overview by Route of Administration\n<\/p>\n<p>\n4.4 Overview by Molecule Type\n<\/p>\n<p>\n4.5 Marketed Drugs Profiles and Sales Forecasts\n<\/p>\n<p>\n<strong>5 Pipeline Drugs Assessment<\/strong>\n<\/p>\n<p>\n5.1 Late-stage Pipeline Drugs\n<\/p>\n<p>\n5.2 Overview by Development Stage\n<\/p>\n<p>\n5.3 Overview by Mechanism of Action\n<\/p>\n<p>\n5.4 Overview by Route of Administration\n<\/p>\n<p>\n5.5 Overview by Molecule Type\n<\/p>\n<p>\n5.6 Drug Specific Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA)\n<\/p>\n<p>\n5.7 Therapy Area and Indication-specific PTSR and LoA\n<\/p>\n<p>\n<strong>6 Clinical Trials Assessment<\/strong>\n<\/p>\n<p>\n6.1 Historical Overview\n<\/p>\n<p>\n6.2 Overview by Phase\n<\/p>\n<p>\n6.3 Overview by Status\n<\/p>\n<p>\n6.4 Overview by Phase for Ongoing and Planned Trials\n<\/p>\n<p>\n6.5 Trials with Virtual Components\n<\/p>\n<p>\n6.6 Geographic Overview\n<\/p>\n<p>\n6.7 Single-Country and Multinational Trials by Region\n<\/p>\n<p>\n6.8 Top 20 Sponsors with Breakdown by Phase\n<\/p>\n<p>\n6.9 Top 20 Sponsors with Breakdown by Status\n<\/p>\n<p>\n6.10 Overview by Endpoint Status\n<\/p>\n<p>\n6.11 Overview by Race and Ethnicity\n<\/p>\n<p>\n6.12 Enrollment Data\n<\/p>\n<p>\n6.13 Top 20 countries for Trial Sites\n<\/p>\n<p>\n6.14 Top 20 Sites Globally\n<\/p>\n<p>\n6.15 Feasibility Analysis &#8211; Geographic Overview\n<\/p>\n<p>\n6.16 Feasibility Analysis &#8211; Benchmark Models\n<\/p>\n<p>\n<strong>7 Deals Landscape<\/strong>\n<\/p>\n<p>\n7.1 Mergers, Acquisitions, and Strategic Alliances by Region\n<\/p>\n<p>\n7.2 Recent Mergers, Acquisitions, and Strategic Alliances\n<\/p>\n<p>\n<strong>8 Commercial Assessment<\/strong>\n<\/p>\n<p>\n8.1 Key Market Players\n<\/p>\n<p>\n<strong>9 Future Market Catalysts<\/strong>\n<\/p>\n<p>\n<strong>10 Appendix<\/strong>\n<\/p>\n<p>\nFor more information about this report visit <a target=\"_blank\" href=\"https:\/\/www.researchandmarkets.com\/reports\/5645167\/waldenstrom-macroglobulinemia-wm-marketed-and?utm_source=BW&amp;utm_medium=PressRelease&amp;utm_code=gw5vj5&amp;utm_campaign=1747120+-+Global+Waldenstrom+Macroglobulinemia+(WM)+Marketed+and+Pipeline+Drugs+Assessment%2C+Clinical+Trials+and+Competitive+Landscape+Report+2022&amp;utm_exec=jamu273prd\" rel=\"nofollow noopener\" shape=\"rect\">https:\/\/www.researchandmarkets.com\/r\/ejw74x<\/a>\n<\/p>\n<p>\nSource: GlobalData\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nResearchAndMarkets.com<br \/>\n<br \/>Laura Wood, Senior Press Manager<br \/>\n<br \/><a target=\"_blank\" href=\"mai&#108;&#116;&#111;&#58;&#x70;&#x72;&#x65;&#x73;&#x73;&#x40;&#x72;ese&#97;&#114;&#99;&#104;&#97;&#x6e;&#x64;&#x6d;&#x61;&#x72;&#x6b;ets&#46;&#99;&#111;&#109;\" rel=\"nofollow noopener\" shape=\"rect\">&#x70;&#x72;&#x65;&#x73;&#115;&#64;&#114;es&#x65;&#x61;&#x72;&#x63;&#x68;&#97;&#110;&#100;ma&#x72;&#x6b;&#x65;&#x74;&#x73;&#46;&#99;&#111;m<\/a><br \/>For E.S.T Office Hours Call 1-917-300-0470<br \/>\n<br \/>For U.S.\/ CAN Toll Free Call 1-800-526-8630<br \/>\n<br \/>For GMT Office Hours Call +353-1-416-8900\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Waldenstrom Macroglobulinemia (WM) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape&#8221; report has been added to ResearchAndMarkets.com&#8217;s offering. This reports provides a data-driven overview of the current and future competitive landscape in Waldenstrom Macroglobulinemia therapeutics. Synopsis In 2022, there will be more than 14,000 incident cases of WM across 16 pharmaceutical &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/global-waldenstrom-macroglobulinemia-wm-marketed-and-pipeline-drugs-assessment-clinical-trials-and-competitive-landscape-report-2022-researchandmarkets-com\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-48099","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Global Waldenstrom Macroglobulinemia (WM) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape Report 2022 - ResearchAndMarkets.com - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/global-waldenstrom-macroglobulinemia-wm-marketed-and-pipeline-drugs-assessment-clinical-trials-and-competitive-landscape-report-2022-researchandmarkets-com\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Global Waldenstrom Macroglobulinemia (WM) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape Report 2022 - ResearchAndMarkets.com - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Waldenstrom Macroglobulinemia (WM) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape&#8221; report has been added to ResearchAndMarkets.com&#8217;s offering. This reports provides a data-driven overview of the current and future competitive landscape in Waldenstrom Macroglobulinemia therapeutics. Synopsis In 2022, there will be more than 14,000 incident cases of WM across 16 pharmaceutical ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/global-waldenstrom-macroglobulinemia-wm-marketed-and-pipeline-drugs-assessment-clinical-trials-and-competitive-landscape-report-2022-researchandmarkets-com\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-08T10:02:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220908005581\/en\/1565529\/21\/logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-waldenstrom-macroglobulinemia-wm-marketed-and-pipeline-drugs-assessment-clinical-trials-and-competitive-landscape-report-2022-researchandmarkets-com\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-waldenstrom-macroglobulinemia-wm-marketed-and-pipeline-drugs-assessment-clinical-trials-and-competitive-landscape-report-2022-researchandmarkets-com\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Global Waldenstrom Macroglobulinemia (WM) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape Report 2022 &#8211; ResearchAndMarkets.com\",\"datePublished\":\"2022-09-08T10:02:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-waldenstrom-macroglobulinemia-wm-marketed-and-pipeline-drugs-assessment-clinical-trials-and-competitive-landscape-report-2022-researchandmarkets-com\\\/\"},\"wordCount\":658,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-waldenstrom-macroglobulinemia-wm-marketed-and-pipeline-drugs-assessment-clinical-trials-and-competitive-landscape-report-2022-researchandmarkets-com\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220908005581\\\/en\\\/1565529\\\/21\\\/logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-waldenstrom-macroglobulinemia-wm-marketed-and-pipeline-drugs-assessment-clinical-trials-and-competitive-landscape-report-2022-researchandmarkets-com\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-waldenstrom-macroglobulinemia-wm-marketed-and-pipeline-drugs-assessment-clinical-trials-and-competitive-landscape-report-2022-researchandmarkets-com\\\/\",\"name\":\"Global Waldenstrom Macroglobulinemia (WM) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape Report 2022 - ResearchAndMarkets.com - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-waldenstrom-macroglobulinemia-wm-marketed-and-pipeline-drugs-assessment-clinical-trials-and-competitive-landscape-report-2022-researchandmarkets-com\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-waldenstrom-macroglobulinemia-wm-marketed-and-pipeline-drugs-assessment-clinical-trials-and-competitive-landscape-report-2022-researchandmarkets-com\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220908005581\\\/en\\\/1565529\\\/21\\\/logo.jpg\",\"datePublished\":\"2022-09-08T10:02:44+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-waldenstrom-macroglobulinemia-wm-marketed-and-pipeline-drugs-assessment-clinical-trials-and-competitive-landscape-report-2022-researchandmarkets-com\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-waldenstrom-macroglobulinemia-wm-marketed-and-pipeline-drugs-assessment-clinical-trials-and-competitive-landscape-report-2022-researchandmarkets-com\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-waldenstrom-macroglobulinemia-wm-marketed-and-pipeline-drugs-assessment-clinical-trials-and-competitive-landscape-report-2022-researchandmarkets-com\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220908005581\\\/en\\\/1565529\\\/21\\\/logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220908005581\\\/en\\\/1565529\\\/21\\\/logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-waldenstrom-macroglobulinemia-wm-marketed-and-pipeline-drugs-assessment-clinical-trials-and-competitive-landscape-report-2022-researchandmarkets-com\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Global Waldenstrom Macroglobulinemia (WM) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape Report 2022 &#8211; ResearchAndMarkets.com\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Global Waldenstrom Macroglobulinemia (WM) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape Report 2022 - ResearchAndMarkets.com - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/global-waldenstrom-macroglobulinemia-wm-marketed-and-pipeline-drugs-assessment-clinical-trials-and-competitive-landscape-report-2022-researchandmarkets-com\/","og_locale":"en_US","og_type":"article","og_title":"Global Waldenstrom Macroglobulinemia (WM) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape Report 2022 - ResearchAndMarkets.com - Pharma Trend","og_description":"DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Waldenstrom Macroglobulinemia (WM) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape&#8221; report has been added to ResearchAndMarkets.com&#8217;s offering. This reports provides a data-driven overview of the current and future competitive landscape in Waldenstrom Macroglobulinemia therapeutics. Synopsis In 2022, there will be more than 14,000 incident cases of WM across 16 pharmaceutical ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/global-waldenstrom-macroglobulinemia-wm-marketed-and-pipeline-drugs-assessment-clinical-trials-and-competitive-landscape-report-2022-researchandmarkets-com\/","og_site_name":"Pharma Trend","article_published_time":"2022-09-08T10:02:44+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220908005581\/en\/1565529\/21\/logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/global-waldenstrom-macroglobulinemia-wm-marketed-and-pipeline-drugs-assessment-clinical-trials-and-competitive-landscape-report-2022-researchandmarkets-com\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/global-waldenstrom-macroglobulinemia-wm-marketed-and-pipeline-drugs-assessment-clinical-trials-and-competitive-landscape-report-2022-researchandmarkets-com\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Global Waldenstrom Macroglobulinemia (WM) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape Report 2022 &#8211; ResearchAndMarkets.com","datePublished":"2022-09-08T10:02:44+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/global-waldenstrom-macroglobulinemia-wm-marketed-and-pipeline-drugs-assessment-clinical-trials-and-competitive-landscape-report-2022-researchandmarkets-com\/"},"wordCount":658,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/global-waldenstrom-macroglobulinemia-wm-marketed-and-pipeline-drugs-assessment-clinical-trials-and-competitive-landscape-report-2022-researchandmarkets-com\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220908005581\/en\/1565529\/21\/logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/global-waldenstrom-macroglobulinemia-wm-marketed-and-pipeline-drugs-assessment-clinical-trials-and-competitive-landscape-report-2022-researchandmarkets-com\/","url":"https:\/\/pharma-trend.com\/en\/global-waldenstrom-macroglobulinemia-wm-marketed-and-pipeline-drugs-assessment-clinical-trials-and-competitive-landscape-report-2022-researchandmarkets-com\/","name":"Global Waldenstrom Macroglobulinemia (WM) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape Report 2022 - ResearchAndMarkets.com - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/global-waldenstrom-macroglobulinemia-wm-marketed-and-pipeline-drugs-assessment-clinical-trials-and-competitive-landscape-report-2022-researchandmarkets-com\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/global-waldenstrom-macroglobulinemia-wm-marketed-and-pipeline-drugs-assessment-clinical-trials-and-competitive-landscape-report-2022-researchandmarkets-com\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220908005581\/en\/1565529\/21\/logo.jpg","datePublished":"2022-09-08T10:02:44+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/global-waldenstrom-macroglobulinemia-wm-marketed-and-pipeline-drugs-assessment-clinical-trials-and-competitive-landscape-report-2022-researchandmarkets-com\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/global-waldenstrom-macroglobulinemia-wm-marketed-and-pipeline-drugs-assessment-clinical-trials-and-competitive-landscape-report-2022-researchandmarkets-com\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/global-waldenstrom-macroglobulinemia-wm-marketed-and-pipeline-drugs-assessment-clinical-trials-and-competitive-landscape-report-2022-researchandmarkets-com\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220908005581\/en\/1565529\/21\/logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220908005581\/en\/1565529\/21\/logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/global-waldenstrom-macroglobulinemia-wm-marketed-and-pipeline-drugs-assessment-clinical-trials-and-competitive-landscape-report-2022-researchandmarkets-com\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Global Waldenstrom Macroglobulinemia (WM) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape Report 2022 &#8211; ResearchAndMarkets.com"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48099","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=48099"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48099\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=48099"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=48099"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=48099"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}